Dapagliflozin in Respiratory Failure in Patients With COVID-19
Public ClinicalTrials.gov record NCT04350593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with coronavirus disease 2019 (COVID-19) in the United States, Brazil, Mexico, Argentina, India, Canada, and United Kingdom. The study is evaluating the effect of dapagliflozin 10 milligrams versus placebo, given once daily for 30 days in addition to background local standard of care therapy, on reducing complications and all-cause mortality, or improving clinical recovery.
Study identification
- NCT ID
- NCT04350593
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 22, 2020 (Actual)
- Primary completion
- Mar 31, 2021 (Actual)
- Completion
- Jun 11, 2021 (Actual)
- Last update posted
- Jun 10, 2022
2020 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Heart Group of the Eastern Shore | Fairhope | Alabama | 36532 | — |
| Baptist Hospital of Miami | Miami | Florida | 33176 | — |
| NorthShore University HealthSystem | Evanston | Illinois | 60201 | — |
| Loyola University | Maywood | Illinois | 60153 | — |
| Ascension - St. Vincent | Indianapolis | Indiana | 46260 | — |
| Lahey Health | Burlington | Massachusetts | 01805 | — |
| McLaren Health Care | Auburn Hills | Michigan | 48326 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Saint Luke's Mid America Heart Institute | Kansas City | Missouri | 64111 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| SUNY Downstate Medical Center | Brooklyn | New York | 11203 | — |
| Maimonides Medical Center | Brooklyn | New York | 11219 | — |
| St. Francis Hospital | Roslyn | New York | 11576 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Lancaster General Hospital | Lancaster | Pennsylvania | 17604 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Clinical Trials Network of Tennessee | Memphis | Tennessee | 38103 | — |
| DHR Health Institute for Research and Development | Edinburg | Texas | 78539 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Sentara Healthcare | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04350593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2022 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04350593 live on ClinicalTrials.gov.